RxDoctor Payments Data

Nishal Brahmbhatt, MD

Critical Care Medicine · Honolulu, HINPI 1003159211

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 97 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Insmed, Inc. at 24.6% of the total. 2025 is the largest year on record at $726, more than ten times the $56 reported in 2019.

$1,879in general payments, 2019–2025

Across 97 payments — averaging $19.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insmed, Inc.$462
  • GSK$455
  • AstraZeneca$333
  • Boehringer Ingelheim$232
  • Advanced Respiratory, Inc$69
  • Philips North America LLC$68
  • plus $260 from 8 others
$55,926in research payments, 2019–2025

Across 16 payments — averaging $3495.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • United Therapeutics Corporation$56K

What the payments were for

  • Food & beverage$1,879100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,879 in reported general payments places this provider in the 65th percentile of 31 critical care medicine providers in Hawaii.

See all critical care medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$38,908
Medicare patients
128
Services billed
375

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate28$386,771
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$43,324
EliquisApixaban13$8,027
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$6,274
Breo ElliptaFluticasone/Vilanterol12$4,965
Wixela InhubFluticasone Propion/Salmeterol27$3,526
Albuterol Sulfate HfaAlbuterol Sulfate61$1,557
Ventolin HfaAlbuterol Sulfate11$596
Omeprazole13$367
Fluticasone Propionate14$351
Montelukast Sodium12$91
Prednisone23$90

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev$232$386,77128 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$455$54,56377 claims
PfizerEliquis$24$8,02713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 31 critical care medicine providers in Hawaii.

Other critical care medicine in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →